Kornimate/medical-research-clean huggingface dataset:
effect of neural mobilization in upper cross syndrome

Conditions: Upper Cross Syndrome

Summary: the purpose of this study is to investigate the effect of neural mobilization in patients with upper cross syndrome.

upper cross syndrome (ucs) is the tightness of the levator scapulae, pectoralis major, and upper trapezius whereas inhibition of serratus anterior, deep neck flexors more specifically scalene, middle trapezius, lower trapezius, and rhomboids. this condition is given its name because a cross can be drawn across the upper body. one arm of the cross indicates the tight muscles and the other arm of the cross indicates the inhibited muscles. people suffering from ucs present with a forward head posture (fhp), hunching of the thoracic spine (rounded upper back), elevated and protracted shoulders, scapular winging, and decreased mobility of the thoracic spine. sometimes, manual work can cause musculoskeletal disorders, for example, the workers who do their work in awkward positions repeat the same action throughout their workday. it was found that ucs causes pain among 24.3% of drivers. also, 35.9% of office workers suffer from the upper cross syndrome and body posture was the leading cause. housewives were also suffering from upper cross syndrome. the reason behind this is that during household tasks they don't keep a good posture which causes them pain and other difficulties. patients complaining of non-traumatic neck pain tend to keep the forward head posture, when compared to people without pain. rounded shoulder has been identified as a leading cause of upper quarter pain. kyphosis, by both clinical and quantitative assessment, causes diminished function especially in tasks that require mobility. the effect of neural mobilization in various diseases and conditions includes increasing nerve conduction and functional status, decreasing pain and subjective symptoms. accordingly, there are no available studies in the literature investigating the effect of neural mobilization on the upper cross syndrome, therefore this is the purpose of the study.

Eligibility criteria:
inclusion criteria: * age ranged from 20 to 50 years. * body mass index ≤30 kg/m². * all participants have a forward head, craniovertebral angle \< 50°. * all participants have round back (kyphosis angle ≥ 42°). * all participants have rounded shoulders of ≥ 52°. * the subjects were chosen from both genders based on an assessment of upper cross syndrome by photogrammetric analysis. * all participants have pain intensity level measured by visual analogue scale (4-8). * all participants tested positive for upper limb tension test of median nerve. exclusion criteria: * history of trauma or surgery in the cervical region. * bone fractures or acute soft tissue injuries. * osteoporosis. * pregnant women. * cancer. * neurological conditions affecting cervical and thoracic spine. * connective tissue disease: this includes diseases such as osteomyelitis, lupus, and scleroderma.
genetic variation - the need for opioids during surgery

Conditions: Pain

Summary: the purpose of this study is to find out if the tetanic noxious stimuli and the measured skin conductance response can be used as a test in patients before surgery to have an indication about what amount of analgesics the patient will need during surgery.

skin conductance (sc) shows the emotional state as reflected in changes in the sympathetic nervous system. during sleep or other states of low basic sympathetic activity, activation of the sympathetic nervous system results in filling of the palmar and plantar sweat glands, and the sc increases transiently before the sweat is removed and the sc decreases again. when a short lasting outgoing sympathetic nervous burst occurs, fluctuations of sc will follow. an increase in the number of sc fluctuations (nscf) can therefore be interpreted as increased activity in this part of the sympathetic nervous system. when remifentanil, an opioid analgetic is given, nscf is reduced. genetic variation influences the pharmacokinetics and the pharmacodynamics of analgesics like morphine derivates and remifentanil. 50 female patients will therefore be blood tested to study if they are val/val or met/met for the comt gene, or if they are homozygous or heterozygous for the 118g allele and the 118a allele. this study will show if skin conductance can be used to measure noxious stimulation response before surgery (by giving a tetanic stimuli), and then predict what level of analgesic a patient will need during surgery.

Eligibility criteria:
inclusion criteria: * women in american society of anesthesiologists (asa) group 1-2 and with body mass index between 20 and 30 and going through laparoscopic surgery at the gynecological department, ullevål university hospital. * normal renal and hepar function (serum albumin and serum creatinine should be within the normal limit). exclusion criteria: * chronic pain in the last 6 months or recent use and abuse of analgesics.

Keywords: remifentanil skin conductance anesthesia analgesics, opioid
study of autologous conditioned serum after anterior cruciate ligament reconstructive surgery

Conditions: Joint Instability

Summary: abstract background pro-inflammatory cytokines play a pivotal role in osteoarthritis, as well as in bone tunnel widening after acl reconstructive surgery. a new treatment option is to administer autologous conditioned serum (acs) containing endogenous anti-inflammatory cytokines including il-1ra and growth factors (igf-1, pdgf and tgf-ß1, among others) in the liquid blood phase. objective the purpose of this trial was to establish whether the osteoclastic effect could be affected by intra-articular application of acs, thus resulting in a potential decrease of knee laxity and leading to a better postoperative outcome. methods in a prospective, randomized, double-blinded, placebo-controlled trial with two parallel groups, 62 patients were treated. bone tunnel width was measured by ct scans, while clinical efficacy was assessed by patient-administered outcome instruments (womac, ikdc 2000) up to one year following the acl reconstruction in patients receiving either acs (group a) or placebo (group b). the investigators compared the levels and dynamics of il-1b concentrations in the synovial liquid and examined the correlation between the levels of il-1b at three different post-operative points. level of evidence therapeutic study, level 1 (randomized controlled trial \[significant differences and narrow confidence intervals\])


Eligibility criteria:
inclusion criteria: eligible patients were: * older than 18 years * prior to each surgery, traumatic acl rupture was determined on the basis of a clinical examination and confirmed by exploratory and therapeutic arthroscopic surgery in accordance with good surgical practice * the same preoperative diagnosis of isolated acl rupture * a knee axis deviation up to 5°; knee osteoarthritis up to grade 1 according to the ao * knee chondral lesion up to grade 2 (outerbridge classification). exclusion criteria: * poor general health as judged by the orthopedic surgeon * concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee * any clinically significant or symptomatic vascular or neurological disorder; crystalline, inflammatory and infectious arthropathies * infections * osteomyelitis * alcohol/drug abuse * known coagulopathy * corticosteroid or anti-coagulant usage, and morbid obesity.

Keywords: acl reconstruction autologous conditioned serum orthokine osteoarthritis interleukin receptor antagonist growth factors womac ikdc
effect of deep brain stimulation on gait of patients with parkinson's disease depending on electrode location in subthalamic area

Conditions: Parkinson's Disease

Summary: deep brain stimulation of stn (subthalamic nucleus) at high frequencies generally improved gait in parkinsonian patients. however, sometimes the investigators observed a gait aggravation either with using high voltage and high frequencies, either because of suboptimal placement of electrode inside forel h2 field. the most frequent hypothesise to explain this gait aggravation is a modulation of the activity of pedunculopontine nucleus due to a diffusion of the electric stimulation current to the fibbers going near stn area. the primary purpose of this study is to compare the effect of deep brain stimulation with high frequency versus low frequency on gait of patients whatever the electrodes placement (stn ou forel fields) and whatever the medication condition (with or without treatment).

a randomized, double-blind, parallel-group study 2 groups of patients: 10 patients with electrodes placed in stn and 10 patients with electrodes placed in forel fields. 1 group of healthy paired-control (n=20). patients will be evaluated without and with treatment on two mornings (j0 and j0+1day). in each condition of treatment, 3 conditions of stimulation were tested: without stimulation; frequency 25hz, frequency 130 hz. evaluations consist on : * motor evaluation (updrs) * gait evaluation (to walk on a gait mat) * stand-walk-sit test

Eligibility criteria:
inclusion criteria: * patients : * men or women aged between 45 -85 years * patients with an idiopathic parkinson's disease according to ukpdsbb criteria * normal neurologic evaluation (except parkinson's disease) * patient treated with a deep brain stimulation according to the french consensus conference of treatment of parkinson's disease (consensus conference proceeding, 2000) * affiliated to national health system * having given their informed consent healthy subject * men or women aged between 45 -85 years * normal neurologic evaluation * affiliated to national health system * having given their informed consent exclusion criteria: * patients : * patients suffering of an atypical parkinson syndrome * patients with locomotive disorders which can interfere in gait evaluation * patients with dementia (mms \<24) * under guardianship * in excluding period for another study * person who participate to an other study healthy subject * subject with locomotive disorders which can interfere in gait evaluation * subject with dementia (mms \<24) * under guardianship * in excluding period for another study

Keywords: parkinson's disease deep brain stimulation gait freezing electrode placements
the individualized management with pegylated-interferon alfa-2a (pegasys) and ribavirin (copegus) offering viral eradication: a study of pegylated-interferon alfa-2a plus ribavirin in participants with chronic hepatitis c (chc) non-genotype 2/3 (improve)

Conditions: Hepatitis C, Chronic

Summary: this study will compare the efficacy and safety of treatment with pegylated-interferon alfa-2a plus ribavirin in participants with non-genotype 2/3 chc who, after 12 weeks of study treatment, have undetectable hepatitis c virus (hcv)-ribonucleic acid (rna) or a greater than or equal to (\>=) 2 log10 drop in hcv-rna. participants will be randomized to receive pegylated-interferon alfa-2a 180 micrograms subcutaneously weekly plus ribavirin (1000-1400 milligram \[mg\]) orally daily for the specified duration, followed by 24 weeks of treatment-free follow-up. participants with detectable hcv-rna and less than (\<) 2 log10 drop in hcv-rna at week 12 will discontinue therapy.


Eligibility criteria:
inclusion criteria: * evidence of chc; * evidence of hepatitis c non-genotype 2 or 3; * compensated liver disease. exclusion criteria: * infection with hcv genotype 2 or 3; * history of having received systemic antiviral therapy with activity against chc \<=3 months prior to start of study; * hepatitis a, hepatitis b or human immunodeficiency virus (hiv) infection; * history or evidence of a medical condition associated with chronic liver disease other than chc.
injection in the treatment of lateral epicondylitis. randomized controlled trial

Conditions: Epicondylitis, Lateral

Summary: the aim of the study is to compare the effectiveness of injection techniques in the treatment of elbow lateral epicondylitis. the functional and pain levels of the patients will be evaluated with scores such as dash, vas, prtee. at the same time, usg imaging will be evaluated before injection and in the third month after injection. the study was planned as a randomized controlled prospective study.

patients diagnosed with epicondylitis in our outpatient clinic will be divided into 3 groups, and patients who will receive saline in 1 group and betamethasone sodium in a group will be selected in accordance with the specified conditions and their treatment will be started, and the treatment will be started, which patient will receive which treatment will be determined by the computerized randomization program. ), 1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), 1 ml saline (0.9 naci), while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, the non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. the injection will be applied to the point with a 23 g needle. after the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. subjects will be asked to do this exercise five times in one session, two sessions a day.examination and functional scores to be applied to the patients during follow-up: vas, dash and prtee scores will be checked in the 1st 6th week, 3rd month, 6th month and 12th month vas: visual analog scale dash: the disabilities of the arm, shoulder and hand prtee: the patient-rated tennis elbow evaluation 2. it will be evaluated by usg in the 3rd month.

Eligibility criteria:
inclusion criteria: 1. patients over the age of 18 2. clinical diagnosis- 3. symptoms lasting more than 3 months and no injection within this period 4. radiologically diagnosed - exclusion criteria: - 1. symptoms for less than 3 months 2. having been given injection treatment within 3 months 3. surgical procedure for lateral epicondylitis 4. having pain caused by the cervical spine 5. restricted elbow range of motion 6.having an elbow bony deformity
a randomized placebo-controlled multicenter trial to evaluate the efficacy and safety of jtr-161, allogeneic human dental pulp stem cell, in patients with acute ischemic stroke (j-repair)

Conditions: Acute Ischemic Stroke

Summary: the objective of this study is to evaluate the safety and efficacy of a single intravenous administration of jtr-161 (allogeneic stem cell product derived from the dental pulp of healthy adult humans) to patients with acute ischemic stroke. this study is comprised of 3 cohorts and conducted in the order of cohort 1, cohort 2 and cohort 3. cohort 1 arm-1: jtr-161, 1 × 10\^8 cells/subject, 6 subjects arm-2: placebo, 2 subjects the data and safety monitoring board (dsmb) and the sponsor will decide whether cohort 2 can be initiated or not. cohort 2 arm-1: jtr-161, 3 × 10\^8 cells/subject, 6 subjects arm-2: placebo, 2 subjects dsmb and the sponsor will decide whether cohort 3 can be initiated or not and the dose of jtr-161 in cohort 3. cohort 3 arm-1: jtr-161, 1 × 10\^8 cells/subject or 3 × 10\^8 cells/subject, 30 subjects arm-2: placebo, 30 subjects


Eligibility criteria:
inclusion criteria: * patients who have ischemic strokes in the anterior circulation * patients whose mrs is 0 or 1 prior to the onset of ischemic stroke * patients whose nihss score of ≥5 to ≤20 at screening * patients who can be administered dosing solutions within 48 h of stroke onset exclusion criteria: * patients who have new ischemic lesion in the cerebellum or brainstem * patients whose consciousness level drops severely * patients whose infarct area is widespread * patients who have a clinically significant hemorrhagic transformation * patients who had seizures after onset of ischemic stroke * patients who have medical history of a neurological event such as stroke or clinically significant head trauma within 180 days prior to giving informed consent * patients who have poor blood pressure control * patients who have poor glycaemic control * patients who have one of the following complications 1. severe liver dysfunction 2. severe kidney dysfunction 3. severe heart failure 4. severe pulmonary dysfunction * patients who have severe infections * patients who have any neurological disorder affecting informed consent or study assessments * patients who have the malignant tumor, or medical history of malignant tumor within 2 years prior to the onset of ischemic stroke * patients who have a contraindication for mri * patients who have thrombocytopenia * patients who have medical history of allergy to products derived from human tissues, bovine or porcine * patients who have medical history of allergy to streptomycin * patients who have undergone splenectomy in the past * patients who have a possibility of transient ischemic attack * patients who are scheduled to undergo revascularization (carotid endarterectomy, stent placement etc.)

Keywords: acute ischemic stroke
multi-center single arm trial to determine the effectiveness of warfarin therapy duration for heparin-induced thrombocytopenia (hit)

Conditions: Heparin-induced Thrombocytopenia

Summary: multi-center single arm trial to determine the effectiveness of warfarin therapy duration for heparin-induced thrombocytopenia (hit)


Eligibility criteria:
inclusion criteria: * patient must be able to provide an informed consent * patient older than 18 years' old * patient with suspected diagnosis of hit, need 2 of the following: have a fall in platelet count of \> 30% from a baseline prior to heparin/lmwh platelet factor 4 (pf4) elisa positive develop skin lesions secondary to subcutaneous heparin with t score more than 4 for those less than 4 we will use serotonin release assay-sra * patient received the bridging therapy of non-heparin anticoagulant * patient is receiving the standard of care treatment for hit * patient is willing to be followed up for by one of the physicians listed in the delegation log * the primary physician responsible for the patient is agreeing for the patient to participate * patients are not involved in a clinical trial for hit management exclusion criteria: * patient is unable to sign an informed consent * patient doesn't have a confirmed diagnosis of hit * patient does not have pulmonary embolus * patient does is not on warfarin for other indications * patient is a known case of hypercoagulable disorder * patient is not willing to come back for follow up * patient is critically ill or has a life expectancy of less than 3 months * pregnancy that is in first trimester. * multi-system organ failure or estimated survival of less than 30 days * uncontrolled hypertension defined as a blood pressure \>180/110 mm hg
an ocular safety study of ivacaftor-treated pediatric patients 11 years of age or younger with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this study is designed to evaluate the risk of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of pediatric patients with cystic fibrosis who are 11 years of age or younger at the time of ivacaftor treatment initiation and are receiving or planning to receive commercially-available ivacaftor in the us.


Eligibility criteria:
inclusion criteria: 1. subject must be 11 years of age or younger at the time of treatment initiation with ivacaftor (as part of clinical trial) or commercially-available ivacaftor. 2. subject must reside in the us and be receiving or planning to receive commercially-available ivacaftor. exclusion criteria: 1. subject is enrolled in an ivacaftor clinical study in which ivacaftor exposure is mandated by the protocol. 2. subject has received surgery for cataracts

Keywords: cystic fibrosis
a real-world data study to evaluate the effectiveness of oca on hepatic outcomes in pbc patients

Conditions: Primary Biliary Cholangitis

Summary: this is an observational, retrospective cohort study, using the uk pbc registry, comparing patients with primary biliary cholangitis (pbc) who failed ursodeoxycholic acid (udca) treatment and were treated with obeticholic acid (oca) to patients with pbc who failed udca treatment and were not treated with second-line therapy. the study is designed to evaluate the effectiveness of oca. all patients who meet diagnostic criteria for pbc in the database between 01 jun 2015 and 31 dec 2021 and who meet all eligibility criteria will be considered for this study.


Eligibility criteria:
key inclusion criteria: 1. definite or probable pbc diagnosis 2. udca failure 3. age ≥18 years at the index date 4. evaluable data for at least 12 months before the index date (inclusive) key exclusion criteria: 1. history or presence of other concomitant liver diseases 2. patients with laboratory values indicative of hepatic decompensation or significant hepatobiliary injury 3. history of liver transplant 4. evidence of oca, fenofibrate, or bezafibrate use 5. history or presence of hepatic decompensating events 6. participation in a clinical trial for a pbc medication

Keywords: primary biliary cholangitis primary biliary cirrhosis pbc hepatic impairment liver
decreasing depression and anxiety and their effect on qol of esrd patients (end-stage renal disease)

Conditions: End-Stage Renal Disease

Summary: this study evaluates the effect of a single cognitive-behavioral intervention (cbi) in a control group against the same cbi plus the strengthening of resiliency skills in an experimental group, on esrd patients.

cognitive behavioral therapy has long been an alternative in the treatment of symptoms of depression and anxiety in patients with chronic diseases such as renal failure, however the combination of therapeutic approaches that include not only pathological but also another more positive approach (as the resilient model), represents a novel proposal for the treatment of negative psychological symptoms and improvement of the quality of life in these patients. the inclusion of the resilient model in a cognitive behavioral intervention serves as a possibility of therapeutic target that could enhance the effectiveness of the treatment.

Eligibility criteria:
inclusion criteria: * older than 18, and younger than 61 years old * depression score in the beck depression inventory (bdi) greater than 30 points. * anxiety score in the beck anxiety inventory (bai) greater than 40 points. * have not been hospitalized over the last 6 months * signing of informed consent exclusion criteria: * may not be able to communicate in the spanish language. * presence of psychiatric comorbidity (suicide ideation or depressive or anxious).

Keywords: hemodialysis resilience cognitive behavioral therapy
achilles tendon for the treatment of gluteus medius insufficiency

Conditions: Arthroplasty Complications; Muscle Weakness; Muscle Atrophy; Muscle Tear

Summary: residual limping after total hip arthroplasty is a serious complication that lacks effective treatment. the purpose of this study is to evaluate a surgical treatment for residual limping and compare its results with non-surgical treatment. our hypothesis is that surgical treatment followed by physiotherapy increases hip function and reduces limping compared with non-surgical treatment with physiotherapy alone.

residual limping due to gluteus medius insufficiency after total hip arthroplasty is a serious complication that lacks effective treatment. the purpose of this study is to evaluate surgical reconstruction of gluteus medius using achilles tendon allograft and compare its results and adverse events with non-surgical treatment. our hypothesis is that surgical reconstruction followed by physiotherapy increases hip function and reduces limping compared with non-surgical treatment with physiotherapy alone.

Eligibility criteria:
inclusion criteria: * persisting limping with positive trendelenburg's sign for at least 12 months after total hip arthroplasty * rupture/avulsion of the gluteus medius tendon verified with ultrasound or mri * leg length discrepancy of less than 1 cm * femoral offset discrepancy of less than 25% exclusion criteria: * neuromuscular disorders

Keywords: gluteus medius limp abductor trendelenburg